Tobacco use disorder
Drug research and approvals for tobacco use disorder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 126 studies of tobacco use disorder are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 126
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- The Effect of Smoking on Salivary and Serum Lipidomic Profiles in Patients With PeriodontitisNCT07942727 · Not reported · Ankara University · starts Nov 11, 2026
- Salivary IL-8 and Serum IL-6 as Biomarkers for Oral Potentially Malignant Disorders in Smokers and Never-SmokersNCT07915570 · Not reported · British University In Egypt · starts Oct 1, 2026
- Effectiveness of Volitional Help Sheets as an Adjunct to Treatment to Promote Behavior Change: A Pilot Study on SmokingNCT07910214 · Not applicable · Clinique de la Mitterie · starts Mar 11, 2026
- §SMOKE Nicotine and Tobacco Youth CohortNCT07910331 · Not reported · University of Southern Denmark · starts Sep 23, 2026
- Modulating Neural Mechanisms of Reward Processing in Tobacco UsersNCT07812753 · Not applicable · Rutgers, The State University of New Jersey · starts Jul 24, 2026
- Adaptation and Testing of a Novel Text-based Tobacco Cessation and Education Intervention in Kenyan Emergency…NCT07734727 · Not applicable · Yale University · starts Nov 1, 2026
- Puff Topography and Sensory Effects Across IQOS Device GenerationsNCT07712887 · Not applicable · American University of Beirut Medical Center · starts Jul 27, 2026
- Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)NCT07711691 · Not applicable · University of California, Irvine · starts Sep 16, 2026
- Brain/Craving Response to Smoking Cues After Oral Nicotine Pouch UseNCT07698470 · Not applicable · University of Southern California · starts Apr 30, 2026
Approved 2
- NicotineNeuronal acetylcholine receptor; alpha4/beta2 agonist
- VareniclineNeuronal acetylcholine receptor; alpha4/beta2 agonist
Phase 3 12 of 14
- BupropionDopamine transporter inhibitor
- NaltrexoneOpioid receptors; mu/kappa/delta antagonist
- TopiramateCarbonic anhydrase II inhibitor
- CelecoxibCyclooxygenase-2 inhibitor
- MethylphenidateDopamine transporter inhibitor
- Curcumin
- FluoxetineSerotonin transporter inhibitor
- AclidiniumMuscarinic acetylcholine receptor M3 antagonist
- FormoterolBeta-2 adrenergic receptor agonist
- NystatinErgosterol sequestering agent
- CytisiniclineNeuronal acetylcholine receptor; alpha4/beta2 partial agonist
- DianiclineNeuronal acetylcholine receptor; alpha4/beta2 partial agonist
Phase 2 12 of 42
- ProgesteroneProgesterone receptor agonist
- BaclofenGABA-B receptor agonist
- SelegilineMonoamine oxidase B inhibitor
- GalantamineAcetylcholinesterase inhibitor
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- AcetylcysteineGlutathione precursor
- Cotinine
- TolcaponeCatechol O-methyltransferase inhibitor
- Insulin humanInsulin receptor agonist
- ZileutonArachidonate 5-lipoxygenase inhibitor
- CycloserineD-alanylalanine synthetase inhibitor
- GuanfacineAdrenergic receptor alpha-2 agonist
Phase 1 or earlier 12 of 23
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- MentholTransient receptor potential cation channel subfamily M member 8 opener
- MemantineGlutamate [NMDA] receptor negative allosteric modulator
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- Phenanthrene
- HaloperidolSerotonin 2a (5-HT2a) receptor antagonist
- LoxapineSerotonin 2a (5-HT2a) receptor antagonist
- AtomoxetineNorepinephrine transporter inhibitor
- OxazepamGABA-A receptor; anion channel positive allosteric modulator
- CarbidopaDOPA decarboxylase inhibitor
- LevodopaDopamine D3 receptor agonist
- ModafinilDopamine transporter inhibitor
How its trials ended
907 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 222 whose ending is known, 55% met their primary endpoint, 10% missed it and 35% stopped early.
- Completed, result not reported51156%
- Met its primary endpoint12314%
- Ongoing11713%
- Status unknown576%
- Stopped: other or unclear485%
- Missed its primary endpoint222%
- Stopped: enrollment or feasibility152%
- Stopped: lack of efficacy51%
- Stopped: sponsor or business decision51%
- Stopped: funding4<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA